Voyager Therapeutics Inc（VYGR）股票分析VYGRVoyager Therapeutics Inc

Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Voyager Therapeutics Inc (VYGR) is currently trading at $1.78, which is close to its 52-week low of $1.68. The stock has seen a significant decline of 55.83% year-to-date, indicating a challenging market environment. The RSI is at 39.49, suggesting that the stock is nearing oversold territory, which could indicate a potential reversal in price. However, the forward P/E ratio is 8.44, which is relatively low compared to industry standards, hinting at potential undervaluation. The main risk is the negative net income, which was reported at -$27.9 million for Q1 2026, indicating ongoing financial struggles. Therefore, while there are some indicators of potential recovery, the overall financial performance and recent price history suggest that it may be prudent to hold rather than buy at this time.

10 analysts cover VYGR: 9 rate it Buy, 1 Hold and 0 Sell. The average price target is 13.20.